Asia Pacific biopharmaceuticals market will grow by 10.3% annually with a total addressable market cap of $1,776.7 billion over 2024-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical trials and approvals for novel biomedicines, escalating healthcare spending, and favorable reimbursement policies.
Highlighted with 41 tables and 85 figures, this 159-page report "Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars), Therapeutic Area, and Country: Trend Forecast and Growth Opportunity" is based on comprehensive research of the entire Asia Pacific biopharmaceuticals market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify the Asia Pacific biopharmaceuticals market in every aspect of the classification from perspectives of Product Type, Testing Service, Raw Material, Classification, Therapeutic Area and Country.
Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Monoclonal Antibodies
o Anti-cancer Monoclonal Antibodies
o Anti-inflammatory Monoclonal Antibodies
o Other Monoclonal Antibodies
• Recombinant Growth Factors
o Erythropoietin
o Granulocyte Colony Stimulating Factor
• Purified Proteins
o Leukemia Inhibitory Factor (LIF)
o P53 Protein
o P38 Protein
o Other Purified Proteins
• Recombinant Proteins
o Serum Albumin
o Amyloid Protein
o Defensin
o Transferrin
• Recombinant Hormones
o Recombinant Human Growth Hormones
o Recombinant Insulin
o Other Recombinant Hormones
• Vaccines
o Recombinant Vaccines
Cancer Vaccines
Malaria Vaccines
Ebola Vaccines
Hepatitis Vaccines
Tetanus Vaccines
Diphtheria Vaccines
Cholera Vaccines
Other Recombinant Vaccines
o Conventional Vaccines
Polio Vaccines
Pox Vaccines
Other Conventional Vaccines
• Recombinant Enzymes
o Enterokinase
o Cyclase
o Caspase
o Cathepsin
• Cell and Gene Therapies
o Allogenic Products
o Autologous Products
o Acellular Products
• Synthetic Immunomodulators
• Other Product Types
o Blood Factors
o Other Products
Based on Testing Service, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Laboratory Testing
• Custom Testing/Customer Proprietary Testing
• Compendial and Multi Compendial Laboratory Testing
By Raw Material, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Formulation Excipients
• Active Pharmaceutical Ingredients (API)
• Other Materials
By Classification, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Innovative Biopharmaceuticals
• Biogenerics and Biosimilars
By Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Oncology
• Inflammatory and Infectious Diseases
• Autoimmune Disorders
• Metabolic Disorders
• Hormonal Disorders
• Cardiovascular Diseases
• Neurological Diseases
• Other Therapeutic Areas
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2023-2033. The breakdown of national markets by Product Type and Therapeutic Area over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 26
2.1.3 Impact of Russia-Ukraine Conflict 28
2.1.4 Impact of Israel-Palestine War 30
2.2 Major Growth Drivers 31
2.3 Market Restraints and Challenges 40
2.4 Emerging Opportunities and Market Trends 43
2.5 Porter's Fiver Forces Analysis 47
3 Segmentation of Asia Pacific Market by Product Type 51
3.1 Market Overview by Product Type 51
3.2 Monoclonal Antibodies 53
3.2.1 Anti-cancer Monoclonal Antibodies 54
3.2.2 Anti-inflammatory Monoclonal Antibodies 55
3.2.3 Other Monoclonal Antibodies 56
3.3 Recombinant Growth Factors 57
3.3.1 Erythropoietin 58
3.3.2 Granulocyte Colony Stimulating Factor 59
3.4 Purified Proteins 60
3.4.1 Leukemia Inhibitory Factor (LIF) 61
3.4.2 P53 Protein 62
3.4.3 P38 Protein 63
3.4.4 Other Purified Proteins 64
3.5 Recombinant Proteins 65
3.5.1 Serum Albumin 66
3.5.2 Amyloid Protein 67
3.5.3 Defensin 68
3.5.4 Transferrin 69
3.6 Recombinant Hormones 70
3.6.1 Recombinant Human Growth Hormones 71
3.6.2 Recombinant Insulin 73
3.6.3 Other Recombinant Hormones 74
3.7 Vaccines 75
3.7.1 Recombinant Vaccines 76
3.7.2 Conventional Vaccines 78
3.8 Recombinant Enzymes 79
3.8.1 Enterokinase 80
3.8.2 Cyclase 81
3.8.3 Caspase 82
3.8.4 Cathepsin 83
3.9 Cell and Gene Therapies 84
3.9.1 Allogenic Products 85
3.9.2 Autologous Products 86
3.9.3 Acellular Products 87
3.10 Synthetic Immunomodulators 88
3.11 Other Product Types 89
3.11.1 Blood Factors 90
3.11.2 Other Products 91
4 Segmentation of Asia Pacific Market by Testing Service 92
4.1 Market Overview by Testing Service 92
4.2 Laboratory Testing 94
4.3 Custom Testing/Customer Proprietary Testing 95
4.4 Compendial and Multi Compendial Laboratory Testing 96
5 Segmentation of Asia Pacific Market by Raw Material 97
5.1 Market Overview by Raw Material 97
5.2 Formulation Excipients 99
5.3 Active Pharmaceutical Ingredients (API) 100
5.4 Other Materials 101
6 Segmentation of Asia Pacific Market by Classification 102
6.1 Market Overview by Classification 102
6.2 Innovative Biopharmaceuticals 104
6.3 Biogenerics and Biosimilars 105
7 Segmentation of Asia Pacific Market by Therapeutic Area 106
7.1 Market Overview by Therapeutic Area 106
7.2 Oncology 108
7.3 Inflammatory and Infectious Diseases 109
7.4 Autoimmune Disorders 110
7.5 Metabolic Disorders 111
7.6 Hormonal Disorders 112
7.7 Cardiovascular Diseases 113
7.8 Neurological Diseases 114
7.9 Other Therapeutic Areas 115
8 Asia-Pacific Market 2023-2033 by Country 116
8.1 Overview of Asia-Pacific Market 116
8.2 Japan 119
8.3 China 122
8.4 Australia 124
8.5 India 126
8.6 South Korea 128
8.7 Rest of APAC Region 130
9 Competitive Landscape 132
9.1 Overview of Key Vendors 132
9.2 New Product Launch, Partnership, Investment, and M&A 136
9.3 Company Profiles 137
Abbott Laboratories 137
Amgen Inc. 139
Astrazeneca PLC 140
Bayer AG 141
Biogen Inc. 142
Bristol-myers Squibb Company (BMS) 143
Eli Lilly and Company 144
F. Hoffmann-La Roche Ltd. 145
Glaxosmithkline PLC 146
Johnson & Johnson 147
Merck & Co. Inc. 148
Novartis Ag 149
Novo Nordisk As 150
Pfizer Inc. 151
Sanofi Sa 152
Sharp Packaging Services 153
Sun Pharmaceutical Industries Ltd. 154
Takeda Pharmaceutical Company Limited 155
Thermo Fisher Scientific Inc. 156
Vertex Pharmaceuticals 157
WuXi AppTec 158
RELATED REPORTS 159
Market Overview
The Asia Pacific Banking as a Service (BaaS) Market is set to experience substantial growth from 2024 to 2034, driven by the region's rapid digitalization, the increasing adoption of cloud-based technologies, and the growing demand for seamless financial services. As fin...
Market Overview
The Asia Pacific Perfume Packaging Market is anticipated to witness robust growth from 2024 to 2034, driven by evolving consumer preferences, rising disposable incomes, and the increasing demand for premium and personalized fragrances. With the region emerging as a globa...
Market Overview
The Asia Pacific Alternate Marine Power Market is set to experience substantial growth from 2024 to 2034, driven by the increasing demand for sustainable and eco-friendly power solutions within the maritime industry. With rising regulations on emissions, the market for a...
Market Overview
The Asia Pacific Bio Vanillin Market is expected to witness robust growth from 2024 to 2034, driven by increasing demand for natural flavoring agents and the rising popularity of bio-based products. The market is projected to reach USD XX.XX billion by 2034, growing at a...
Market Overview
The Asia Pacific AI-Enabled Biometric Market is set to experience robust growth from 2024 to 2034, driven by the increasing adoption of artificial intelligence (AI) technologies in biometric systems to enhance security, identity verification, and surveillance. The market...
Market Overview
The Asia Pacific Commercial Vehicle Telematics Market is poised for significant growth from 2024 to 2034, driven by the increasing demand for real-time vehicle tracking, fleet management, and enhanced operational efficiency across various industries. The market is expect...
Market Overview
The Asia Pacific Passive Optical Network (PON) Market is poised for robust growth between 2024 and 2034, driven by the increasing demand for high-speed broadband connectivity, especially in emerging economies. The market is expected to reach USD XX.XX billion by 2034, gr...
Market Overview
The Asia Pacific Safety Valves Market is expected to witness substantial growth from 2024 to 2034, driven by increasing industrial activities and the rising demand for enhanced safety standards across key sectors. The market is projected to reach USD XX.XX billion by 203...
Market Overview
The Asia Pacific Vanadium Market is poised for substantial growth from 2024 to 2034, driven by increasing demand across various industries and technological advancements in vanadium production. The market is projected to reach USD XX.XX billion by 2034, growing at a comp...
Market Overview
The Asia Pacific Vascular Closure Devices Market is anticipated to experience substantial growth from 2024 to 2034. The market's expansion is fueled by advancements in vascular closure technologies, increasing prevalence of cardiovascular diseases, and the growing adopti...